{"disease":{"id":"esophageal-squamous-cell-carcinoma","name":"Esophageal Squamous Cell Carcinoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":24},"drugs":{"marketed":[{"drug_id":"tislelizumab","indication_name":"Esophageal Squamous Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic esophageal squamous cell carcinoma (ESCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"chembl-chembl1789844","indication_name":"Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"disitamab-vedotin","indication_name":"Locally advanced or metastatic esophageal squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Disitamab vedotin","generic_name":"disitamab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"human epidermal growth factor receptor 2 (HER2)","drug_class":"antibody-drug conjugate","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01077817","title":"Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)","phase":"","overall_status":"COMPLETED","enrollment_count":684815,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT01688908","title":"Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33948,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT04609813","title":"Esophageal cAncer Screening Trial","phase":"","overall_status":"COMPLETED","enrollment_count":14597,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT04170257","title":"Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07201571","title":"A Retrospective Cohort Study of Patients Who Underwent Curative-intent Esophagectomy for ESCC at a Tertiary Referral Center in South Korea","phase":"","overall_status":"COMPLETED","enrollment_count":3131,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT04290806","title":"Registry Platform Gastric/Esophageal Cancer (SAPHIR)","phase":"","overall_status":"RECRUITING","enrollment_count":1900,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT04152499","title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT05775419","title":"Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC","phase":"NA","overall_status":"RECRUITING","enrollment_count":1216,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05142709","title":"Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.","phase":"","overall_status":"COMPLETED","enrollment_count":1197,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04460352","title":"Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1020,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT07224750","title":"A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07223424","title":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":880,"lead_sponsor_name":"Diwakar Davar","has_results":false},{"nct_id":"NCT04949256","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":864,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04009265","title":"Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":819,"lead_sponsor_name":"Fujian Medical University Union Hospital","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07147361","title":"Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04543617","title":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":760,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07343869","title":"Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":750,"lead_sponsor_name":"Société Française d'Endoscopie Digestive","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03748134","title":"Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":746,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT07251062","title":"A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":737,"lead_sponsor_name":"CSPC Megalith Biopharmaceutical Co.,Ltd.","has_results":false},{"nct_id":"NCT06190652","title":"Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.","phase":"","overall_status":"COMPLETED","enrollment_count":728,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT05208762","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT04210115","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":703,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04848753","title":"Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":663,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT03783442","title":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":649,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT03206125","title":"NCI UNC Project ESCC","phase":"","overall_status":"TERMINATED","enrollment_count":648,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03790553","title":"Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":646,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05078047","title":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":646,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT04550260","title":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":640,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06333665","title":"PPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients With Esophageal Squamous Cell Cancer Undergoing Minimally Invasive Esophagectomy","phase":"","overall_status":"COMPLETED","enrollment_count":605,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT03900871","title":"Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT03160209","title":"HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06241079","title":"Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":582,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT06192212","title":"PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive Esophagectomy","phase":"","overall_status":"COMPLETED","enrollment_count":577,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT04187352","title":"A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":540,"lead_sponsor_name":"CStone Pharmaceuticals","has_results":false},{"nct_id":"NCT06863831","title":"A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":536,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06169163","title":"Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms","phase":"","overall_status":"RECRUITING","enrollment_count":518,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT03430843","title":"A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":512,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT06644781","title":"A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":510,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT06252974","title":"Accurate Diagnosis of the Invasion Depth in ESCC by a Deep Neural Network Analysis of NBI Endoscopy Data","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06194734","title":"A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":490,"lead_sponsor_name":"Beijing Konruns Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03958890","title":"A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":489,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT05983432","title":"Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":470,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT07463573","title":"QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":466,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04138212","title":"Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":456,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT06656091","title":"A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":450,"lead_sponsor_name":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","has_results":false},{"nct_id":"NCT06063941","title":"High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy","phase":"NA","overall_status":"COMPLETED","enrollment_count":450,"lead_sponsor_name":"Xijing Hospital of Digestive Diseases","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}